WO2020013781A3 - Effet synergique de flurbiprofène et d'agent protecteur gastrique pour le traitement de la douleur et de l'inflammation - Google Patents

Effet synergique de flurbiprofène et d'agent protecteur gastrique pour le traitement de la douleur et de l'inflammation Download PDF

Info

Publication number
WO2020013781A3
WO2020013781A3 PCT/TR2019/050200 TR2019050200W WO2020013781A3 WO 2020013781 A3 WO2020013781 A3 WO 2020013781A3 TR 2019050200 W TR2019050200 W TR 2019050200W WO 2020013781 A3 WO2020013781 A3 WO 2020013781A3
Authority
WO
WIPO (PCT)
Prior art keywords
flurbiprofen
protective agent
inflammation
pain
treatment
Prior art date
Application number
PCT/TR2019/050200
Other languages
English (en)
Other versions
WO2020013781A2 (fr
Inventor
Mehmet Nevzat PISAK
Original Assignee
Pisak Mehmet Nevzat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pisak Mehmet Nevzat filed Critical Pisak Mehmet Nevzat
Publication of WO2020013781A2 publication Critical patent/WO2020013781A2/fr
Publication of WO2020013781A3 publication Critical patent/WO2020013781A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique orale à libération immédiate sous une forme galénique pharmaceutique unitaire comprenant du flurbiprofène ou un sel pharmaceutiquement acceptable de celui-ci et un antagoniste du récepteur H2 en tant qu'agent gastro-protecteur, l'antagoniste du récepteur H2 étant présent en une quantité de 5 à 80 % en poids de flurbiprofène. La présente invention concerne une composition pharmaceutique orale à libération immédiate sous une forme galénique pharmaceutique unitaire comprenant du flurbiprofène ou un sel pharmaceutiquement acceptable de celui-ci, un antagoniste du récepteur H2 ou un sel pharmaceutiquement acceptable de celui-ci et un carbonate, l'antagoniste du récepteur H2 étant présent en une quantité de 10 à 80 % en poids de flurbiprofène.
PCT/TR2019/050200 2018-03-27 2019-03-27 Effet synergique de flurbiprofène et d'agent protecteur gastrique pour le traitement de la douleur et de l'inflammation WO2020013781A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
TR2018/04315 2018-03-27
TR201804315 2018-03-27
TR2018/05998 2018-04-27
TR201805998 2018-04-27
TR201807777 2018-05-31
TR2018/07777 2018-05-31

Publications (2)

Publication Number Publication Date
WO2020013781A2 WO2020013781A2 (fr) 2020-01-16
WO2020013781A3 true WO2020013781A3 (fr) 2020-03-19

Family

ID=68887105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050200 WO2020013781A2 (fr) 2018-03-27 2019-03-27 Effet synergique de flurbiprofène et d'agent protecteur gastrique pour le traitement de la douleur et de l'inflammation

Country Status (1)

Country Link
WO (1) WO2020013781A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194003B1 (en) * 1997-05-22 2001-02-27 The Boots Company Plc Process for making flurbiprofen lozenges
US20030069255A1 (en) * 2001-06-01 2003-04-10 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2682109A1 (fr) * 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations à libération immédiate combinée de flurbiprofène et famotidine
US20150290174A1 (en) * 2014-04-11 2015-10-15 Resuscitate MOE LLC Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine
US20180008712A1 (en) * 2014-12-25 2018-01-11 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002182A1 (fr) 1996-07-12 1998-01-22 Novartis Consumer Health S.A. Combinations pharmaceutiques orales d'anti-inflammatoires non steroïdiens et de terpenoïdes
US20050163847A1 (en) 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US8569375B2 (en) 2008-08-22 2013-10-29 Reckitt Benckiser Healthcare (Uk) Limited Compositions
DE102012209150B3 (de) 2012-05-31 2013-04-11 Siemens Aktiengesellschaft Adaptives Röntgenfilter und Verfahren zur Veränderung der lokalen Intensität einer Röntgenstrahlung

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194003B1 (en) * 1997-05-22 2001-02-27 The Boots Company Plc Process for making flurbiprofen lozenges
US20030069255A1 (en) * 2001-06-01 2003-04-10 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2682109A1 (fr) * 2012-07-05 2014-01-08 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations à libération immédiate combinée de flurbiprofène et famotidine
US20150290174A1 (en) * 2014-04-11 2015-10-15 Resuscitate MOE LLC Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine
US20180008712A1 (en) * 2014-12-25 2018-01-11 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol

Also Published As

Publication number Publication date
WO2020013781A2 (fr) 2020-01-16

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
WO2012079092A3 (fr) Compositions d'undécanoate de testostérone
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MX2010003923A (es) Formulacion farmaceutica de valsartan.
MX354423B (es) Formulaciones de rasagilina de liberación prolongada y usos de las mismas.
EP2493312A4 (fr) Compositions pharmaceutiques solides contenant un inhibiteur d'intégrase
PT2205279E (pt) Associação farmacêutica de aliscireno e valsartan
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2021014774A (es) Formulaciones de liberacion modificada y usos de las mismas.
WO2018027084A3 (fr) Combinaison d'antagonistes de récepteur du glucagon et d'inhibiteurs de la voie pi3k pour le traitement du cancer
TW200603816A (en) Risedronate compositions and their methods of use
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
JP2016505050A5 (fr)
MX2021008208A (es) Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
MX2013002649A (es) Agente terapeutico contra el dolor.
RU2016137926A (ru) Композиции грапипранта и способы их применения
WO2020013776A3 (fr) Effet synergique du naproxène et un agent protecteur gatrique qui traite la douleur et l'inflammation
WO2020013781A3 (fr) Effet synergique de flurbiprofène et d'agent protecteur gastrique pour le traitement de la douleur et de l'inflammation
WO2020032883A3 (fr) Effets synergiques d'une nouvelle formulation de kétoprofène comprenant un agent gastro-protecteur
WO2019203759A3 (fr) Associations d'étodolac et d'antagonistes du récepteur h2 pour le traitement de la douleur et de l'inflammation
JP2012097034A5 (fr)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26.01.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19820911

Country of ref document: EP

Kind code of ref document: A2